CN117797151A - Quinoline derivatives combined with chemotherapeutics for treating non-small cell lung cancer - Google Patents
Quinoline derivatives combined with chemotherapeutics for treating non-small cell lung cancer Download PDFInfo
- Publication number
- CN117797151A CN117797151A CN202410036103.7A CN202410036103A CN117797151A CN 117797151 A CN117797151 A CN 117797151A CN 202410036103 A CN202410036103 A CN 202410036103A CN 117797151 A CN117797151 A CN 117797151A
- Authority
- CN
- China
- Prior art keywords
- lung cancer
- cell lung
- small cell
- chemotherapeutic agent
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title claims abstract description 52
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 title claims abstract description 49
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title description 3
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 16
- 239000002246 antineoplastic agent Substances 0.000 claims description 52
- 229940127089 cytotoxic agent Drugs 0.000 claims description 47
- 150000001875 compounds Chemical class 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 36
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 28
- 229960004562 carboplatin Drugs 0.000 claims description 28
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 24
- 229940002612 prodrug Drugs 0.000 claims description 21
- 239000000651 prodrug Substances 0.000 claims description 21
- 229960005079 pemetrexed Drugs 0.000 claims description 18
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 18
- 229960005277 gemcitabine Drugs 0.000 claims description 16
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 16
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 14
- 229960004316 cisplatin Drugs 0.000 claims description 14
- -1 bifurouracil Chemical compound 0.000 claims description 12
- 229910052697 platinum Inorganic materials 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 238000001959 radiotherapy Methods 0.000 claims description 11
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 9
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 9
- 229960003668 docetaxel Drugs 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 229960003048 vinblastine Drugs 0.000 claims description 9
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 9
- 229960002066 vinorelbine Drugs 0.000 claims description 9
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 9
- 229930012538 Paclitaxel Natural products 0.000 claims description 8
- IIJQICKYWPGJDT-UHFFFAOYSA-L azane;cyclobutane-1,1-dicarboxylate;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound N.N.[Pt+2].OC(=O)C1(C([O-])=O)CCC1.OC(=O)C1(C([O-])=O)CCC1 IIJQICKYWPGJDT-UHFFFAOYSA-L 0.000 claims description 8
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 claims description 8
- 229950007221 nedaplatin Drugs 0.000 claims description 8
- 229960001756 oxaliplatin Drugs 0.000 claims description 8
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 8
- 229960001592 paclitaxel Drugs 0.000 claims description 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 8
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 claims description 7
- 229940123237 Taxane Drugs 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 229960001674 tegafur Drugs 0.000 claims description 6
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 claims description 6
- 229960004528 vincristine Drugs 0.000 claims description 6
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 6
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 6
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims description 5
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 5
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 5
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 claims description 5
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 5
- 229960004117 capecitabine Drugs 0.000 claims description 5
- 229960003261 carmofur Drugs 0.000 claims description 5
- 229960005420 etoposide Drugs 0.000 claims description 5
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 5
- 229960002949 fluorouracil Drugs 0.000 claims description 5
- 229960004768 irinotecan Drugs 0.000 claims description 5
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 5
- 229960004355 vindesine Drugs 0.000 claims description 5
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims description 5
- 229950005454 doxifluridine Drugs 0.000 claims description 4
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 claims description 4
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 3
- 229940044683 chemotherapy drug Drugs 0.000 claims description 3
- 150000005699 fluoropyrimidines Chemical class 0.000 claims description 3
- 229960000303 topotecan Drugs 0.000 claims description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 3
- HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 claims description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 229930192392 Mitomycin Natural products 0.000 claims description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 229960002756 azacitidine Drugs 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- VKFAUCPBMAGVRG-UHFFFAOYSA-N dipivefrin hydrochloride Chemical compound [Cl-].C[NH2+]CC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 VKFAUCPBMAGVRG-UHFFFAOYSA-N 0.000 claims description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 2
- 229960001101 ifosfamide Drugs 0.000 claims description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960004857 mitomycin Drugs 0.000 claims description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- UFPFGVNKHCLJJO-SSKFGXFMSA-N (2s)-n-[(1s)-1-cyclohexyl-2-[(2s)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide Chemical compound C1([C@H](NC(=O)[C@H](C)NC)C(=O)N2[C@@H](CCC2)C=2SC=C(N=2)C(=O)C=2C=CC(F)=CC=2)CCCCC1 UFPFGVNKHCLJJO-SSKFGXFMSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 1
- 229960002550 amrubicin Drugs 0.000 claims 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 229960002707 bendamustine Drugs 0.000 claims 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- AHJUHHDDCJQACA-UHFFFAOYSA-N encequidar Chemical compound C1=CC=C2OC(C(=O)NC3=CC(OC)=C(OC)C=C3C=3N=NN(N=3)C3=CC=C(C=C3)CCN3CCC=4C=C(C(=CC=4C3)OC)OC)=CC(=O)C2=C1 AHJUHHDDCJQACA-UHFFFAOYSA-N 0.000 claims 1
- 229940121438 encequidar Drugs 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- FIOKOSHFWPOUGX-UHFFFAOYSA-N n-[1-(4-chlorophenyl)ethyl]-2-(4-nitrophenoxy)acetamide Chemical compound C=1C=C(Cl)C=CC=1C(C)NC(=O)COC1=CC=C([N+]([O-])=O)C=C1 FIOKOSHFWPOUGX-UHFFFAOYSA-N 0.000 claims 1
- 229950011498 plinabulin Drugs 0.000 claims 1
- UNRCMCRRFYFGFX-TYPNBTCFSA-N plinabulin Chemical compound N1C=NC(\C=C/2C(NC(=C\C=3C=CC=CC=3)/C(=O)N\2)=O)=C1C(C)(C)C UNRCMCRRFYFGFX-TYPNBTCFSA-N 0.000 claims 1
- 229950006896 sapacitabine Drugs 0.000 claims 1
- LBGFKUUHOPIEMA-PEARBKPGSA-N sapacitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](C#N)[C@H](O)[C@@H](CO)O1 LBGFKUUHOPIEMA-PEARBKPGSA-N 0.000 claims 1
- 229960004964 temozolomide Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 4
- 150000003248 quinolines Chemical class 0.000 abstract description 4
- KSMZEXLVHXZPEF-UHFFFAOYSA-N 1-[[4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)C=CN=C2C=C1OCC1(N)CC1 KSMZEXLVHXZPEF-UHFFFAOYSA-N 0.000 abstract description 2
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 230000000694 effects Effects 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 206010041823 squamous cell carcinoma Diseases 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 6
- 208000009956 adenocarcinoma Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 102000001301 EGF receptor Human genes 0.000 description 5
- 108060006698 EGF receptor Proteins 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 230000001394 metastastic effect Effects 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 230000000306 recurrent effect Effects 0.000 description 5
- 206010041067 Small cell lung cancer Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical group FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 108091008794 FGF receptors Proteins 0.000 description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 101100091501 Mus musculus Ros1 gene Proteins 0.000 description 2
- 108091008606 PDGF receptors Proteins 0.000 description 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000003849 large cell carcinoma Diseases 0.000 description 2
- 238000009115 maintenance therapy Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 2
- 210000002620 vena cava superior Anatomy 0.000 description 2
- 229960000922 vinflunine Drugs 0.000 description 2
- NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- MLMQPDHYNJCQAO-UHFFFAOYSA-N 3,3-dimethylbutyric acid Chemical compound CC(C)(C)CC(O)=O MLMQPDHYNJCQAO-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960000510 ammonia Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940090570 dipivefrin hydrochloride Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000001370 mediastinum Anatomy 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940066012 pemetrexed 500 mg Drugs 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The application belongs to the field of medicines, provides a quinoline derivative combined chemotherapeutic medicine for treating non-small cell lung cancer, and particularly relates to application of a 1- [ [ [4- (4-fluoro-2-methyl-1H-indol-5-yl) oxy-6-methoxyquinolin-7-yl ] oxy ] methyl ] cyclopropylamine combined chemotherapeutic medicine in treating non-small cell lung cancer.
Description
The invention relates to a Chinese application (the invention name is that quinoline derivatives are combined with chemotherapeutics to treat non-small cell lung cancer; the application date is 2019, 3, 4 and 201910159974.7).
Technical Field
The invention belongs to the field of medicines, and particularly relates to a quinoline derivative combined with a chemotherapeutic drug for treating non-small cell lung cancer.
Background
Cancer is a major public health problem in many parts of the world. Among them, lung cancer has high morbidity and mortality, and is a major cause of cancer death worldwide. In 2012, approximately 180 ten thousand people worldwide are new to develop lung cancer, and 160 ten thousand people die. Lung cancer is a common cause of cancer death in men, and is second only to breast cancer in women, second to the list. In recent years, the incidence and death of lung cancer in China are rapidly increasing. Currently, based on the biological properties and prognosis of lung cancer, the World Health Organization (WHO) classifies it into two major categories: non-small cell lung cancer (non-small cell lung cancer, NSCLC) and small cell lung cancer (small cell lung cancer, SCLC). Non-small cell lung cancer includes squamous cell carcinoma (squamous carcinoma), adenocarcinoma, large cell carcinoma, which has slower growth and division of cancer cells and relatively late diffusion metastasis compared to small cell carcinoma. Non-small cell lung cancer accounts for about 80% of all lung cancers, with about 75% of patients found to be in the middle and late stages with very low survival rates of 5 years.
Tyrosine kinases are a group of enzymes that catalyze the phosphorylation of protein tyrosine residues, play an important role in intracellular signal transduction, and are involved in the regulation, signaling and development of normal cells, and are also closely related to proliferation, differentiation, migration and apoptosis of tumor cells. Many receptor tyrosine kinases are involved in tumor formation and can be classified into Epidermal Growth Factor Receptor (EGFR), platelet Derived Growth Factor Receptor (PDGFR), vascular Endothelial Growth Factor Receptor (VEGFR), fibroblast Growth Factor Receptor (FGFR), etc. according to the structure of their extracellular regions.
Chemotherapy is one of the most effective means for treating cancer at present, and is also called as three major treatment means of cancer together with surgery and radiotherapy. The combination of chemotherapeutic agents has the following advantages: (1) The synergistic effect is generated in the aspect of killing tumor cells, thereby improving the curative effect; (2) Reducing the dosage and/or time of administration of the single agent, thereby reducing toxicity; (3) reduces the likelihood of cancer cells developing drug resistance; (4) The combination of a chemotherapeutic drug which enters the brain can prevent or treat brain metastasis.
Disclosure of Invention
In one aspect, the present application provides a pharmaceutical combination comprising: (i) Compound I, or a pharmaceutically acceptable salt, hydrate or prodrug thereof; and (ii) a chemotherapeutic agent.
In another aspect, the present application provides a pharmaceutical combination comprising: (i) Compound I, or a pharmaceutically acceptable salt, hydrate or prodrug thereof; and (ii) a chemotherapeutic agent, optionally in combination with radiation therapy, in the manufacture of a medicament for the treatment of non-small cell lung cancer.
In some embodiments, a pharmaceutical combination is provided, comprising: (i) Compound I, or a pharmaceutically acceptable salt, hydrate or prodrug thereof; and (ii) platinum and pemetrexed, optionally in combination with radiotherapy, in the manufacture of a medicament for the treatment of non-small cell lung cancer. In some embodiments, a pharmaceutical combination is provided, comprising: (i) Compound I, or a pharmaceutically acceptable salt, hydrate or prodrug thereof; and (ii) platinum and gemcitabine, optionally in combination with radiation therapy, in the manufacture of a medicament for the treatment of non-small cell lung cancer. In some embodiments, a combination is provided, comprising: (i) Compound I, or a pharmaceutically acceptable salt, hydrate or prodrug thereof; and (ii) carboplatin and pemetrexed, in the manufacture of a medicament for treating non-squamous non-small cell lung cancer. In some specific embodiments, a combination is provided comprising: (i) Compound I, or a pharmaceutically acceptable salt, hydrate or prodrug thereof; and (ii) carboplatin and pemetrexed, in the manufacture of a medicament for treating adenocarcinoma non-small cell lung cancer. In some specific embodiments, a combination is provided comprising: (i) Compound I, or a pharmaceutically acceptable salt, hydrate or prodrug thereof; and (ii) carboplatin and gemcitabine, in the manufacture of a medicament for the treatment of squamous cell lung carcinoma.
In yet another aspect, the present application provides a method of treating non-small cell lung cancer comprising: administering to a patient in need thereof an effective amount of (I) compound I, or a pharmaceutically acceptable salt, hydrate or prodrug thereof; and (ii) a chemotherapeutic agent, and optionally radiation therapy.
In some embodiments, the present application provides a treatmentA method of non-small cell lung cancer comprising: administering to a patient in need thereof an effective amount of (I) compound I, or a pharmaceutically acceptable salt, hydrate or prodrug thereof; and (ii) pemetrexed and carboplatin. Wherein the dosage of pemetrexed is 250-600mg/m 2 Preferably 300-500mg/m 2 The method comprises the steps of carrying out a first treatment on the surface of the Every 3 weeks (i.e., 21 days) is a cycle, and is administered on the first day of each cycle. Carboplatin was administered once every 3 weeks (i.e., 21 days); in some embodiments, carboplatin is administered on the first day of each cycle. Preferably, the non-small cell lung cancer is non-squamous. In some embodiments, the non-small cell lung cancer is adenocarcinoma.
In some embodiments, the present application provides a method of treating non-small cell lung cancer comprising: administering to a patient in need thereof an effective amount of (I) compound I, or a pharmaceutically acceptable salt, hydrate or prodrug thereof; and (ii) gemcitabine and carboplatin. Wherein the administration dose of gemcitabine is 0.7-1.0g/m 2 Preferably 0.8-1.0g/m 2 The method comprises the steps of carrying out a first treatment on the surface of the Every 3 weeks (i.e., 21 days) is a cycle, and is administered on the first and eighth days of each cycle. Carboplatin was administered once every 3 weeks (i.e., 21 days); in some embodiments, carboplatin is administered on the first day of each cycle. In some embodiments, the non-small cell lung cancer is squamous cancer.
In yet another aspect, the present application provides a kit for use in the treatment of a combination of non-small cell lung cancer comprising: (i) Compound I, or a pharmaceutically acceptable salt, hydrate or prodrug thereof; and (ii) a chemotherapeutic agent;
optionally in combination with radiation therapy,
the method is characterized in that: (i) Contained in a first compartment, and (ii) contained in a second compartment.
In this application, compound I has the chemical name 1- [ [ [4- (4-fluoro-2-methyl-1H-indol-5-yl) oxy-6-methoxyquinolin-7-yl ] oxy ] methyl ] cyclopropylamine, having the structural formula:
in this application, prodrugs of compound I are converted in vivo to the free base form of compound I. Pharmaceutically acceptable salts of compound I can be produced from various organic and inorganic acids according to methods well known in the art. "pharmaceutically acceptable salts" include, but are not limited to, acid addition salts with mineral acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, and the like; or with an organic acid such as acetic acid, trifluoroacetic acid, propionic acid, caproic acid, heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1, 2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-chlorobenzenesulfonic acid, p-toluenesulfonic acid, 3-phenylpropionic acid, trimethylacetic acid, t-butylacetic acid, dodecylsulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, and the like. In some embodiments, the pharmaceutically acceptable salt of compound I is the hydrochloride salt of compound I. In some embodiments, the pharmaceutically acceptable salt of compound I is a monohydrochloride salt of compound I. In some embodiments, the pharmaceutically acceptable salt of compound I is a dihydrochloride salt of compound I. In some embodiments, the hydrochloride salt of compound I is in crystalline form. In some embodiments, the pharmaceutically acceptable salt of compound I is a crystal of compound I dihydrochloride. In some embodiments, the pharmaceutically acceptable salt of compound I is the maleate salt of compound I.
Examples of such chemotherapeutic agents include, but are not limited to, one or more of alkylating agents, podophyllones, camptothecins, taxanes, antimetabolites, antibiotic antineoplastic agents, and examples that may be cited include, but are not limited to, platinum-based agents (e.g., oxaliplatin, cisplatin, carboplatin, nedaplatin, dicycloplatin), fluoropyrimidine derivatives (e.g., gemcitabine, capecitabine, fluorouracil, bifluoride, doxifluridine, tegafur, carmofur), taxanes (e.g., paclitaxel, albumin-bound paclitaxel, and docetaxel), camptothecins (e.g., camptothecins, hydroxycamptothecins, irinotecan, topotecan), vinorelbine, vincristine, vindesine, vinflunine (vinflunine), pemetrexed, etoposide, mitomycin, ifosfamide, cyclophosphamide, azamide, azacitidine, ammonia, methotrexate, stand-62, and other than one of the two of the salts, the salts of fluzamide, the other than one of the two of the salts, the salts of fluzamide, the salts of the two of the salts of fluxaprop-IV, the salts of the two of the drugs.
In some embodiments, the chemotherapeutic agent is a platinum-based agent.
In some embodiments, the chemotherapeutic agent is a platinum agent and one or more of the chemotherapeutic agents described above.
In some embodiments, the chemotherapeutic agent is a platinum-based agent (e.g., one of oxaliplatin, cisplatin, carboplatin, nedaplatin, or dicycloplatin) and a taxane (e.g., one of paclitaxel, albumin-bound paclitaxel, or docetaxel); in some embodiments, the chemotherapeutic agent is carboplatin or paclitaxel; in some embodiments, the chemotherapeutic agent is carboplatin and albumin-bound paclitaxel. In some embodiments, the chemotherapeutic agent is carboplatin or docetaxel; in some embodiments, the chemotherapeutic agent is cisplatin or paclitaxel; in some embodiments, the chemotherapeutic agent is cisplatin-and albumin-bound paclitaxel. In some embodiments, the chemotherapeutic agent is cisplatin or docetaxel.
In some embodiments, the chemotherapeutic agent is a platinum-based agent (e.g., one of oxaliplatin, cisplatin, carboplatin, nedaplatin, or dicycloplatin) and a vinblastine (e.g., one of vinorelbine, vinblastine, vincristine, vindesine, or vinblastine); in some embodiments, the chemotherapeutic agent is carboplatin or vinorelbine. In some embodiments, the chemotherapeutic agent is cisplatin or vinorelbine.
In some embodiments, the chemotherapeutic agent is a platinum-based agent (e.g., one of oxaliplatin, cisplatin, carboplatin, nedaplatin, or dicycloplatin) and a fluoropyrimidine derivative (e.g., one of gemcitabine, capecitabine, fluorouracil, bififluridine, doxifluridine, tegafur, carmofur, trifluoretide); in some embodiments, the chemotherapeutic agent is a platinum-based agent (e.g., one of oxaliplatin, cisplatin, carboplatin, nedaplatin, or dicycloplatin) and gemcitabine; in some embodiments, the chemotherapeutic agent is cisplatin or gemcitabine.
In some embodiments, the chemotherapeutic agent is a platinum-based agent (e.g., one of oxaliplatin, cisplatin, carboplatin, nedaplatin, or dicycloplatin) and pemetrexed. In some embodiments, the chemotherapeutic agent is cisplatin or pemetrexed. In some embodiments, the chemotherapeutic agent is carboplatin or pemetrexed.
In some embodiments, the chemotherapeutic agent is a platinum-based agent (e.g., one of oxaliplatin, cisplatin, carboplatin, nedaplatin, or dicycloplatin) and etoposide. In some embodiments, the chemotherapeutic agent is cisplatin and etoposide, or carboplatin and etoposide.
In some embodiments, the chemotherapeutic agent is pemetrexed.
In some embodiments, the chemotherapeutic agent is pemetrexed and a taxane (e.g., one of paclitaxel, albumin-bound paclitaxel, or docetaxel); in some embodiments, the chemotherapeutic agent is pemetrexed and docetaxel.
In some embodiments, the chemotherapeutic agent is pemetrexed and a vinblastine (e.g., one of vinorelbine, vinblastine, vincristine, vindesine, or vinblastine); in some embodiments, the chemotherapeutic agent is pemetrexed and vinorelbine.
In some embodiments, the chemotherapeutic agent is a camptothecin (e.g., one of camptothecin, hydroxycamptothecin, irinotecan, or topotecan); in some embodiments, the chemotherapeutic agent is irinotecan.
In some embodiments, the chemotherapeutic agent is a fluoropyrimidine derivative (e.g., one of gemcitabine, capecitabine, fluorouracil, bififluridine, doxifluridine, tegafur, carmofur, trifluoracetam) and a taxane (e.g., one of paclitaxel, albumin-bound paclitaxel, or docetaxel); in some embodiments, the chemotherapeutic agent is gemcitabine and docetaxel.
In some embodiments, the chemotherapeutic agent is a fluoropyrimidine derivative (e.g., one of gemcitabine, capecitabine, fluorouracil, bififluridine, deoxyfluorouridine, tegafur, carmofur, trifluoracetin) and a vincristine (e.g., one of vinorelbine, vinblastine, vincristine, vindesine, or vinfuneraline); in some embodiments, the chemotherapeutic agent is gemcitabine and vinorelbine.
In some embodiments, the chemotherapeutic agent is trifluoracetam and dipivefrin hydrochloride. In some embodiments, the chemotherapeutic agent is encquidar mesylate and paclitaxel.
In some embodiments, the chemotherapeutic agent is tegafur.
In this application, the histological typing of non-small cell lung cancer includes, but is not limited to, adenocarcinoma, squamous cell carcinoma, large cell carcinoma or undefined non-small cell lung cancer; clinical stages include, but are not limited to, locally advanced, and/or advanced (e.g., stage IIIB/IV) and/or metastatic non-small cell lung cancer. Wherein metastatic non-small cell lung cancer includes, but is not limited to, focal single metastasis, disseminated metastasis, diffuse metastasis; the metastatic lesions include, but are not limited to, lymph nodes, pleura, bone, brain, pericardium, adrenal gland, liver; in some embodiments, the small cell lung cancer is brain-transferred non-small cell lung cancer. In some embodiments, the non-small cell lung cancer is recurrent non-small cell lung cancer, including but not limited to intrabronchial obstructive non-small cell lung cancer, resectable recurrent non-small cell lung cancer, recurrent non-small cell lung cancer of the mediastinum lymph node, superior Vena Cava (SVC) obstructive non-small cell lung cancer, severe hemoptysis non-small cell lung cancer. In some embodiments, the non-small cell lung cancer is a non-small cell lung cancer that develops or recurs after having been previously subjected to at least one chemotherapy. In some embodiments, the non-small cell lung cancer is non-small cell lung cancer that is intolerant to chemotherapy. In a preferred embodiment, the non-small cell lung cancer is non-small cell lung cancer that has not previously been treated systematically. In some embodiments, the non-small cell lung cancer is preferably squamous carcinoma; in some embodiments, the non-small cell lung cancer is a non-squamous carcinoma; in some specific embodiments, the non-small cell lung cancer is adenocarcinoma.
In the application, the non-small cell lung cancer is non-small cell lung cancer with negative gene mutation; the genetic mutations are EGFR genetic mutations (including but not limited to, exon 18, exon 19 (e.g., DEL 19), exon 21 (e.g., L858R), exon 20 insertion (e.g., T790M)), ALK rearrangements, and/or ROS1 mutations.
The components of the pharmaceutical combination of the present invention may optionally be combined with one or more pharmaceutically acceptable carriers, wherein the components may each independently, or some or all of them together comprise pharmaceutically acceptable carriers and/or excipients. The pharmaceutical combinations of the invention may be formulated separately from each other or some or all of them may be formulated together. Preferably, the components of the pharmaceutical combination are formulated separately or each as a suitable pharmaceutical composition. In some embodiments, the pharmaceutical combinations of the present application may be formulated into pharmaceutical compositions suitable for single or multiple administration. In some particular embodiments, the pharmaceutical composition containing compound I, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, may be selected from solid pharmaceutical compositions including, but not limited to, tablets or capsules.
The components of the pharmaceutical combinations of the present application may each be administered alone, or some or all of them may be co-administered. The components of the pharmaceutical combinations of the present application may be administered substantially simultaneously, or some or all of them may be administered substantially simultaneously.
The components of the pharmaceutical combinations of the present application may each be administered independently, or some or all of them together, by suitable routes, including, but not limited to, oral or parenteral (via intravenous, intramuscular, topical or subcutaneous routes). In some embodiments, the components of the pharmaceutical combinations of the present application may each be administered orally or by injection, e.g., intravenously or intraperitoneally, independently, or in combination with some or all of them.
The components of the pharmaceutical combinations of the present application may each independently, or some or all of them together, be in a suitable dosage form including, but not limited to, tablets, troches, pills, capsules (e.g., hard capsules, soft capsules, enteric capsules, microcapsules), elixirs, granules, syrups, injections (intramuscular, intravenous, intraperitoneal), granules, emulsions, suspensions, solutions, dispersions, and dosage forms of sustained release formulations for oral or non-oral administration.
In this application, the components of the pharmaceutical combination may be administered to a patient as separate entities (e.g., pharmaceutical compositions) simultaneously, alternately or sequentially, wherein the active ingredients administered to the patient reach therapeutically effective levels. In some embodiments, the individual active components may be packaged, marketed, or administered as a completely separate pharmaceutical composition.
The amount of each component administered in the pharmaceutical combinations of the present application may be determined according to the severity of the disease, the response of the disease, any treatment-related toxicity, the age and health of the patient. In some embodiments, the daily dose of compound I, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, is from 6 mg to 20 mg; preferably 8mg to 16 mg; more preferably 8mg to 14 mg; most preferably 8mg, 10mg or 12 mg. Compound I, or a pharmaceutically acceptable salt, hydrate or prodrug thereof, may be administered one or more times daily, preferably once daily; in some embodiments, compound I, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, is administered once daily in an oral solid formulation.
The dosage regimen may be determined in general terms of the activity, toxicity, tolerance of the drug, etc. Typically, the components of the pharmaceutical combinations of the present application may be administered according to dosing regimens known in the art. In some embodiments, compound I, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, is administered in a divided dosing regimen; the interval administration includes administration period and withdrawal period, and can be administered once or multiple times daily during administration period. In some embodiments, the ratio of dosing period to withdrawal period in days is from 2:0.5 to 5, preferably from 2:0.5 to 3, more preferably from 2:0.5 to 2, more preferably from 2:0.5 to 1. In some embodiments, administration is stopped for 1 week for 2 weeks. In certain particular embodiments, compound I, or a pharmaceutically acceptable salt, hydrate, or prodrug thereof, is administered orally at a dose of 8, 10, and/or 12mg once daily for 2 weeks, and for 1 week in a continuous dosing regimen.
In some embodiments, pemetrexed is administered intravenously at a dose of 500mg/m 2 The method comprises the steps of carrying out a first treatment on the surface of the Every 3 weeks (i.e., 21 days) is a cycle, and is administered on the first day of each cycle.
In some embodiments, gemcitabine is administered intravenously at a dose of 1.0g/m 2 Every 3 weeks (i.e., 21 days) is a cycle, and is administered on the first and eighth days of each cycle.
In some embodiments, the dose of carboplatin administered intravenously is calculated according to formulas well known to those skilled in the art at an AUC of 5mg/ml/min, and is administered once every 3 weeks (i.e., 21 days) for a period.
The pharmaceutical combinations of the invention are particularly effective in inhibiting tumor growth, survival and metastasis thereof, have a synergistic effect, or are capable of increasing the patient's tolerance to the relevant treatment. In some embodiments, sensitivity to chemotherapy and/or radiation therapy may be induced or rebuilt or enhanced in the patient. In the present invention, the amount of each therapeutic agent alone is not sufficient to achieve the effect achieved by administration of the pharmaceutical combination, and wherein the combined effect of the therapeutic agents is better than the total therapeutic effect achieved by each therapeutic agent at that dose.
The dosages and ranges provided herein are based on the molecular weight of the free base form of compound I, unless otherwise indicated.
For the purposes of this application, the following terms, as used in the specification and claims, shall have the following meanings, unless otherwise indicated.
"patient" means a mammal, preferably a human.
By "pharmaceutically acceptable" is meant that it is used to prepare a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes that it is acceptable for human pharmaceutical use.
By "therapeutically effective amount" is meant an amount of a compound that, when administered to a human being for treating a disease, is sufficient to effect treatment of the disease.
"treatment" means any administration of a therapeutically effective amount of a compound and includes:
(1) Inhibiting the disease in a human experiencing or exhibiting the pathology or symptomology of the disease (i.e., arresting further development of the pathology and/or symptomology), or
(2) Improving the disease in a human experiencing or exhibiting the pathology or symptomology of the disease (i.e., reversing the pathology and/or symptomology).
"treatment failure" refers to intolerance of toxic or side effects, disease progression during treatment, or recurrence after treatment has ended.
"optionally" means with or without.
"CR" means complete remission, i.e., disappearance of all target lesions, all pathological lymph nodes (including target nodules and non-target nodules) short diameter must be reduced to < 10mm.
By "PR" is meant partial remission, the sum of target lesion diameters is reduced by at least 30% from baseline levels.
"ORR" refers to the objective rate of remission, which is the sum of the ratio of complete remission and partial remission. That is, orr=cr+pr.
"PD" refers to disease progression, relative increase in diameter and diameter of at least 20% relative to the minimum sum of all measured diameters of target lesions throughout the course of the study (baseline value if the baseline measurement is minimal); and must meet the relative increase in diameter sum of at least 5mm, if a new lesion appears, it is also considered as disease progression.
"SD" means that the disease is stable, the target lesions are reduced to a degree that does not reach PR levels, nor are increased to a degree that does not reach PD levels, between the two.
"DCR" refers to disease control rate and includes the percentage of patients who are fully relieved, partially and stable for disease and who have sustained more than 4 weeks of disease in which efficacy can be assessed.
"PFS" refers to progression-free survival from random grouping until the time of objective progression of the tumor or death of the patient.
"OS" total lifetime refers to the time from the start of the group to death due to any source. Subjects who were not visited, in days, were generally counted as dead from the last follow-up time.
Detailed Description
The present application is further illustrated below in conjunction with specific embodiments. It should be understood that these examples are presented by way of illustration only and are not intended to limit the scope of the present application.
Example 1
Locally advanced (IIIb), metastatic or recurrent (stage IV) NSCLC, driving gene negative (EGFR/ALK/ROS 1), 19 patients who had not received systemic anti-tumor treatment against advanced disease and who were pathologically examined as adenocarcinoma, which were not surgically treated and did not receive radical simultaneous radiotherapy and chemotherapy, were histologically or cytologically confirmed. The dosing scheme is as follows: pemetrexed 500mg/m 2 Combined carboplatin (auc=5), administered intravenously 1 time every 3 weeks; in combination with An Luoti Ni hydrochloride capsule, an Luoti Ni is administered orally at a dose of 12mg, 1 time daily, and continuously administered for 2 weeks to stop for 1 week, i.e. 3 weeks (21 days) is a administration period. After 4-6 cycles of combination, maintenance therapy was performed with An Luoti n+pemetrexed. The dose administered may be adjusted down, for example 10% or 20% of the dose, and An Luoti Ni may be adjusted down to 10mg or 8mg during the course of treatment, depending on the patient's tolerance and adverse effects.
In this study, efficacy was evaluated and data analyzed every 2 cycles (C2, i.e., 6 weeks). The main curative effect index is the safety of observing the combined administration and the Objective Remission Rate (ORR); the secondary efficacy indicators are observed patient Progression Free Survival (PFS), disease Control Rate (DCR), total survival (OS).
The results of the patient efficacy evaluation are shown in table 1 below.
Table 1 results of evaluation of efficacy in patients
Example 2
Locally advanced (IIIb), metastatic or recurrent (stage IV) NSCLC, driving gene negative (EGFR/ALK/ROS 1) which were not treated surgically or by cytology, and which were not treated by systemic anti-tumor therapy against advanced disease, and 7 patients with squamous cell carcinoma by pathological examination. The dosing scheme is as follows: gemcitabine 1.0g/m 2 (d 1, d8 days of administration), in combination with carboplatin (auc=5), administered intravenously 1 time every 3 weeks; in combination with An Luoti Ni hydrochloride capsule, an Luoti Ni is administered orally at a dose of 12mg, 1 time daily, and continuously administered for 2 weeks to stop for 1 week, i.e. 3 weeks (21 days) is a administration period. After 4-6 cycles of combination administration, maintenance therapy was performed with An Luoti Ni. The dose administered may be adjusted down, for example 10% or 20% of the dose, and An Luoti Ni may be adjusted down to 10mg or 8mg during the course of treatment, depending on the patient's tolerance and adverse effects.
In this study, efficacy was evaluated every 2 courses (C2, i.e., 6 weeks) and data analysis was performed. The main curative effect index is the safety of observing the combined administration and the Objective Remission Rate (ORR); the secondary efficacy indicators are observed subject Disease Control Rate (DCR), progression Free Survival (PFS), total survival (OS).
The results of the patient efficacy evaluation are shown in table 2 below.
TABLE 2 evaluation results of efficacy in squamous carcinoma patients
Claims (10)
1. A pharmaceutical combination, comprising: (i) Compound I, or a pharmaceutically acceptable salt, hydrate or prodrug thereof; and (ii) a chemotherapeutic agent
2. The pharmaceutical combination of claim 1, characterized in that the chemotherapeutic drug is one or more of alkylating agents, podophyllons, camptothecins, taxanes, antimetabolites, antibiotic antitumor drugs.
3. The pharmaceutical combination according to claim 2, characterized in that the chemotherapeutic agent comprises, but is not limited to, a platinum-based agent: oxaliplatin, cisplatin, carboplatin, nedaplatin, and dicycloplatin; fluoropyrimidine derivatives: gemcitabine, capecitabine, fluorouracil, bifurouracil, doxifluridine, tegafur, carmofur, and trifluoretide; taxanes: paclitaxel, albumin-bound paclitaxel, and docetaxel; camptothecins: camptothecine, hydroxycamptothecine, irinotecan, topotecan; vinblastine: vinorelbine, vinblastine, vincristine, vindesine, and vinfuning; one or two or three of pemetrexed, etoposide, irinotecan, mitomycin, ifosfamide, cyclophosphamide, azacytidine, amrubicin, methotrexate, bendamustine, epirubicin, doxorubicin, temozolomide, LCL-161, KML-001, sapacitabine, plinabulin, troxifogline, dipivefrine hydrochloride, tigaone, and encequidar.
4. The pharmaceutical combination of claim 3, wherein the chemotherapeutic agent is carboplatin or pemetrexed.
5. The pharmaceutical combination of claim 4, wherein the chemotherapeutic agents carboplatin and gemcitabine.
6. Use of a pharmaceutical combination according to any one of claims 1 to 5 for the manufacture of a medicament for the treatment of non-small cell lung cancer.
7. The use according to claim 6, characterized in that the non-small cell lung cancer is squamous or non-squamous cell lung cancer.
8. Use according to claim 6 or 7, characterized in that it is combined with radiotherapy.
9. A method of treating non-small cell lung cancer, comprising: administering to a patient in need thereof an effective amount of (I) compound I, or a pharmaceutically acceptable salt, hydrate or prodrug thereof; and (ii) a chemotherapeutic agent, and optionally radiation therapy.
10. A kit for use in a pharmaceutical combination for treating non-small cell lung cancer, comprising: (i) Compound I, or a pharmaceutically acceptable salt, hydrate or prodrug thereof; and (ii) a chemotherapeutic agent, and optionally radiation therapy.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410036103.7A CN117797151A (en) | 2019-03-04 | 2019-03-04 | Quinoline derivatives combined with chemotherapeutics for treating non-small cell lung cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910159974.7A CN111643502A (en) | 2019-03-04 | 2019-03-04 | Quinoline derivatives combined with chemotherapeutic drugs for treating non-small cell lung cancer |
CN202410036103.7A CN117797151A (en) | 2019-03-04 | 2019-03-04 | Quinoline derivatives combined with chemotherapeutics for treating non-small cell lung cancer |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910159974.7A Division CN111643502A (en) | 2019-03-04 | 2019-03-04 | Quinoline derivatives combined with chemotherapeutic drugs for treating non-small cell lung cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117797151A true CN117797151A (en) | 2024-04-02 |
Family
ID=72340563
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910159974.7A Pending CN111643502A (en) | 2019-03-04 | 2019-03-04 | Quinoline derivatives combined with chemotherapeutic drugs for treating non-small cell lung cancer |
CN202410036103.7A Pending CN117797151A (en) | 2019-03-04 | 2019-03-04 | Quinoline derivatives combined with chemotherapeutics for treating non-small cell lung cancer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910159974.7A Pending CN111643502A (en) | 2019-03-04 | 2019-03-04 | Quinoline derivatives combined with chemotherapeutic drugs for treating non-small cell lung cancer |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN111643502A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI845578B (en) * | 2018-12-14 | 2024-06-21 | 香港商慧源香港創新有限公司 | Therapeutic combinations of orally administered irinotecan and a p-gp inhibitor for the treatment of cancer |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8148532B2 (en) * | 2007-03-14 | 2012-04-03 | Guoqing Paul Chen | Spiro substituted compounds as angiogenesis inhibitors |
AU2017205749B2 (en) * | 2016-01-08 | 2021-12-23 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof |
-
2019
- 2019-03-04 CN CN201910159974.7A patent/CN111643502A/en active Pending
- 2019-03-04 CN CN202410036103.7A patent/CN117797151A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN111643502A (en) | 2020-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2429838C2 (en) | Combined chemotherapy | |
EP3231797B1 (en) | Quinoline derivative against non-small cell lung cancer | |
CN111643503A (en) | Quinoline derivatives for the treatment of non-small cell lung cancer | |
WO2017013160A1 (en) | 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers | |
CN109069500B (en) | Quinoline derivative for treating gastric cancer | |
CN110650741A (en) | Quinoline derivatives for the treatment of colorectal cancer | |
CN115025090A (en) | Application of quinoline derivative in treatment of esophageal cancer, and treatment method, pharmaceutical composition and kit thereof | |
CN103561734A (en) | Synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck | |
CN112638385B (en) | Quinoline derivatives for the treatment of brain tumors | |
CN114173785A (en) | Aminopyridine derivatives for the treatment of non-small cell lung cancer | |
CN113116895A (en) | Quinoline derivatives for the treatment of neuroblastoma | |
CN117797151A (en) | Quinoline derivatives combined with chemotherapeutics for treating non-small cell lung cancer | |
CN112584834B (en) | Quinoline derivatives for the treatment of extranodal NK/T cell lymphoma | |
US20130338129A1 (en) | Method of treating refractory cancer | |
WO2022017508A1 (en) | Combination therapy of parp inhibitors | |
CN111821302A (en) | Quinolines for the combined treatment of chondrosarcoma | |
CN112533600B (en) | Quinoline derivatives for the treatment of small cell lung cancer | |
CN111939165B (en) | Application of non-natural ginsenoside 3 beta-O-Glc-DM in preparation of medicine for preventing or treating glioblastoma | |
CN115484955A (en) | Aminopyridine derivatives for the treatment of disorders of MET gene abnormality | |
CN116440134A (en) | Quinoline derivatives for the treatment of non-small cell lung cancer | |
WO2021224381A1 (en) | Combination therapy for treating cancer | |
CN113750096A (en) | Quinoline derivatives for the treatment of peripheral T cell lymphoma | |
CN111714498A (en) | Quinoline derivatives for the treatment of ovarian cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |